Biotech Roundup: Heart-disease biomarkers, drugs that go too far, “non-profit” drugs
Cautionary tales: An occasional look at events with potential long-term impact for biotechnology
Personalized medicine takes a hit -- Scientists have spent more than a decade scouring the human genome to identify genetic alterations that might predict your risk of developing, say, heart trouble or cancer. Now, however, a new study (subscription required) Wednesday in the Journal of the American Medical Association suggests that many of these disease "biomarkers" identified so far may be little more than junk. (For a lay review of the report, click here.)
The main problem here is that "personalized ... » Continue reading